+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Ovarian Cancer Treatment Drugs Companies in China

  • PDF Icon

    Report

  • 88 Pages
  • August 2024
  • Region: China
  • AMID Co
  • ID: 3453740

China's demand for Ovarian Cancer Treatment Drugs will continue to grow at 12% by 2033.

This study focuses on China’s Ovarian Cancer Treatment Drugs industry assessments and company profiles. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s major producers for industrial and consumer products. Far outpacing other economies in the world, China is the world’s fastest growing market for the consumptions of goods and services. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption and capital investment for over two decades. Rapid consolidation between medium and large players is anticipated since the Chinese government has been encouraging industry consolidation with an effort to regulate the industry and to improve competitiveness in the world market.

Although China has enjoyed the benefits of an expanding market for production and distribution, the industry is suffering from minimal innovation and investment in R&D and new product development. The sector’s economies of scale have yet to be achieved. Most domestic manufacturers lack the autonomic intellectual property and financial resources to develop their own brand name products.

This new study analyzes the industry structure, capacities and output. Major producers' production locations, market shares and profiles are presented. The primary and secondary research is done in China in order to access up-to-date government regulations, market information and industry data. Data were collected from the Chinese government publications, Chinese language newspapers and magazines, industry associations, local governments’ industry bureaus, industry publications, and our in-house databases.

Table of Contents

INTRODUCTION
  • Report Scope and Methodology
  • Executive Summary
OVARIAN CANCER TREATMENT DRUGS INDUSTRY ASSESSMENTS
  • Ovarian Cancer Treatment Drugs Industry Structure
  • Market Size
  • Market Growth Drivers
  • Ovarian Cancer Treatment Drugs Sales Volume
  • Major Producer Facility Locations
  • Major Producers’ Sales Volume and Market Share
  • Paclitaxel
  • Platinum Anticancer Drugs
  • Fluoropyrimidines
  • Anthracycline Antibiotics
  • Therapertic Antibody
  • Small Molecules Drug
  • Aromatase Inhibitors (Targeted Therapy Drug)
  • Anti-estrogens
  • Aromatase Inhibitors (Endocrine Therapy Drug)
LH-RH
  • Labor Cost
  • Potential Entrants
  • Major Distributors
  • Major Foreign Investment
  • Technology Development
OVARIAN CANCER TREATMENT DRUGS PRODUCER DIRECTORY
  • Ovarian Cancer Treatment Drugs Producer Profiles and DIRECTORY
LIST OF TABLES
INTRODUCTION
  • Economic Outlook Summary
OVARIAN CANCER TREATMENT DRUGS INDUSTRY ASSESSMENTS
  • Chemotherapeutic Drug Sales Volume and Market Share by Drugs Classification
  • Targeted Therapy Drug Sales Volume and Market Share by Drugs Classification
  • Endocrine Therapy Drug Sales Volume and Market Share by Drugs Classification
  • Ovarian Cancer Treatment Drugs Sales Volume
  • Major Producer Facility Location
  • Major Ovarian Cancer Treatment Drugs Producer Sales Volume and Market Share
  • Major Foreign Investments in China
LIST OF CHARTS
INTRODUCTION
  • Ovarian Cancer Treatment Drugs Sales Volume
OVARIAN CANCER TREATMENT DRUGS INDUSTRY ASSESSMENTS
  • Chemotherapeutic Drug Market Share by Drugs Classification
  • Targeted Therapy Drug Market Share by Drugs Classification
  • Endocrine Therapy Drug Market Share by Drugs Classification
  • Ovarian Cancer Treatment Drugs Sales Volume

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Wuhan Wuyao Pharmaceutical Co., Ltd
  • Beijing Zizhu Pharmaceutical Co., Ltd